Bridging the gap between genetics and pharmacology. We deliver high-precision drug response profiling, accurately resolving complex *CYP450* haplotypes to power the future of personalized medicine.
Translating raw genomic variants into highly standardized pharmacogene haplotypes.
Overcoming the limitations of short-read NGS. We specialize in resolving highly homologous regions like the CYP2D6/CYP2D7 locus, accurately detecting hybrid genes and structural copy number variants (CNVs) that dictate ultra-rapid or poor metabolizer phenotypes.
High-resolution (4-field) HLA typing from NGS data to predict severe cutaneous adverse reactions (SCARs) to drugs like Abacavir and Carbamazepine.
Illumina Global Screening Array (GSA), Thermo Fisher PharmacoScan. Highly cost-effective for large population-scale PGx screening.
Illumina NovaSeq/NextSeq for targeted AmpliSeq PGx panels. PacBio Revio and Oxford Nanopore are highly recommended for fully resolving the CYP2D6 locus via long-read amplicon sequencing.
PharmacoScan or Array-based Data
TAT: 10 - 14 Days
Deliverables: Genotype calling, Star Allele assignments, Metabolizer Phenotype reports, and standard CPIC drug-gene pair actionable recommendations.
Deep Target Capture + Long Read Integration
TAT: 4 - 6 Days
Deliverables: Full BAM/VCF generation, complex Structural Variant (SV) resolution for CYP2D6, high-res HLA typing, and comprehensive clinical integration reports.
We bridge the gap between bioinformatics and pharmacy. Our reports are formatted to be instantly readable by clinicians and pharmacologists, highlighting "Red Flag" drug interactions based on the patient's genetic profile.
For research cohorts, we provide aggregated frequency data, population allele distributions, and methodology ready for submission to pharmacology and precision medicine journals.
| Designed by DigitalSEO | Sitemap